IL159966A0 - Nucleic acids, polypeptides, and methods for modulating apoptosis - Google Patents

Nucleic acids, polypeptides, and methods for modulating apoptosis

Info

Publication number
IL159966A0
IL159966A0 IL15996602A IL15996602A IL159966A0 IL 159966 A0 IL159966 A0 IL 159966A0 IL 15996602 A IL15996602 A IL 15996602A IL 15996602 A IL15996602 A IL 15996602A IL 159966 A0 IL159966 A0 IL 159966A0
Authority
IL
Israel
Prior art keywords
methods
apoptosis
polypeptides
nucleic acids
dhs
Prior art date
Application number
IL15996602A
Other languages
English (en)
Original Assignee
Senesco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/909,796 external-priority patent/US6867237B1/en
Application filed by Senesco Inc filed Critical Senesco Inc
Publication of IL159966A0 publication Critical patent/IL159966A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
IL15996602A 2001-07-23 2002-07-23 Nucleic acids, polypeptides, and methods for modulating apoptosis IL159966A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/909,796 US6867237B1 (en) 2001-07-23 2001-07-23 DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans
US10/141,647 US7166467B2 (en) 2001-07-23 2002-05-07 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
PCT/US2002/023254 WO2003010286A2 (en) 2001-07-23 2002-07-23 Nucleic acids, polypeptides, and methods for modulating apoptosis

Publications (1)

Publication Number Publication Date
IL159966A0 true IL159966A0 (en) 2004-06-20

Family

ID=26839315

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15996602A IL159966A0 (en) 2001-07-23 2002-07-23 Nucleic acids, polypeptides, and methods for modulating apoptosis

Country Status (12)

Country Link
US (3) US7166467B2 (de)
EP (1) EP1546375B1 (de)
JP (2) JP2005519583A (de)
KR (1) KR100944938B1 (de)
CN (1) CN100352923C (de)
AT (1) ATE489478T1 (de)
AU (1) AU2002324519B2 (de)
CA (2) CA2857312A1 (de)
DE (1) DE60238449D1 (de)
IL (1) IL159966A0 (de)
NZ (1) NZ531225A (de)
WO (1) WO2003010286A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381708B2 (en) 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
US7217517B2 (en) * 2001-07-23 2007-05-15 Senesco Technologies, Inc. Nucleic acids, polypeptides, and methods for modulating apoptosis
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
US7968523B2 (en) 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
WO2004078940A2 (en) * 2003-03-05 2004-09-16 Senesco Technologies, Inc. USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1
CN101014708B (zh) * 2003-03-05 2011-11-02 森尼斯科技术公司 反义寡核苷酸或siRNA在抑制eIF-5A1表达中的应用
NZ544159A (en) * 2003-06-06 2009-04-30 Senesco Technologies Inc Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics
US20140371299A1 (en) * 2004-06-07 2014-12-18 Senesco Technologies, Inc. Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
TW200615001A (en) * 2004-07-20 2006-05-16 Senesco Technologies Inc Use of apoptosis-specific eIF-5A siRNAs and antisense polynucleotides to inhibit/suppress an inflammatory response
EP1959010A3 (de) * 2004-12-03 2009-02-25 Senesco Technologies, Inc. Apoptosespezifisches eIF-5A und Polynukleotide zu seiner Kodierung
NZ569075A (en) * 2005-12-13 2011-12-22 Senesco Technologies Inc Use of elF-5A to kill multiple myeloma cells
AU2007226878A1 (en) * 2006-03-20 2007-09-27 Senesco Technologies, Inc. A novel method of protecting islet cells from apoptosis during the donor harvesting process
CA2717637A1 (en) 2008-03-07 2009-09-17 Senesco Technologies, Inc. Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a desired polynucleotide
JP5578522B2 (ja) 2008-05-27 2014-08-27 義規 世古 アポトーシス誘導薬
US8445638B2 (en) 2008-09-03 2013-05-21 Senesco Technologies, Inc. Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells
CN114231551B (zh) * 2021-12-24 2023-09-29 云南大学 蛋白在促进昆虫淋巴细胞凋亡和/或防治害虫中的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2941668A1 (de) * 1979-10-15 1981-04-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München Kardiotachometer
CA1199371A (en) * 1982-12-03 1986-01-14 Orest Z. Roy Ultrasonic enhancement of cardiac contractility synchronised with ecg event or defibrillation pulse
US4936304A (en) * 1985-10-07 1990-06-26 Thomas Jefferson University Pacing system and method for cardiac pacing as a function of determined myocardial contractility
US5527336A (en) * 1986-12-09 1996-06-18 Boston Scientific Corporation Flow obstruction treatment method
US4881549A (en) * 1987-05-29 1989-11-21 Marquette Electronics Apparatus and method for obtaining ultrasonic backcatter measurement from tissue
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1327838C (fr) * 1988-06-13 1994-03-15 Fred Zacouto Dispositif implantable de protection contre les affections liees a la coagulation sanguine
US4917115A (en) * 1988-07-11 1990-04-17 Vitatron Medical B. V. Pacing system and method for physiological stimulation of the heart utilizing Doppler means
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5220924A (en) * 1989-09-28 1993-06-22 Frazin Leon J Doppler-guided retrograde catheterization using transducer equipped guide wire
US5168064A (en) * 1990-04-20 1992-12-01 The Regents Of The University Of California Endo-1,4-β-glucanase gene and its use in plants
EP0474957A3 (en) * 1990-09-11 1992-06-24 Bozidar Ferek-Petric Ultrasonic doppler synchronized cardiac electrotherapy device
US5156154A (en) * 1991-03-08 1992-10-20 Telectronics Pacing Systems, Inc. Monitoring the hemodynamic state of a patient from measurements of myocardial contractility using doppler ultrasound techniques
US5156157A (en) * 1991-03-08 1992-10-20 Telectronics Pacing Systems, Inc. Catheter-mounted doppler ultrasound transducer and signal processor
US5183040A (en) * 1991-03-08 1993-02-02 Telectronics Pacing Systems, Inc. Apparatus and method for detecting abnormal cardiac rhythms using an ultrasound sensor in an arrhythmia control system
US5188106A (en) * 1991-03-08 1993-02-23 Telectronics Pacing Systems, Inc. Method and apparatus for chronically monitoring the hemodynamic state of a patient using doppler ultrasound
US5139020A (en) * 1991-03-08 1992-08-18 Telectronics Pacing Systems, Inc. Method and apparatus for controlling the hemodynamic state of a patient based on systolic time interval measurements detecting using doppler ultrasound techniques
JPH05233318A (ja) * 1992-02-18 1993-09-10 Nec Corp マイクロプロセッサ
US5197467A (en) * 1992-06-22 1993-03-30 Telectronics Pacing Systems, Inc. Multiple parameter rate-responsive cardiac stimulation apparatus
US5830848A (en) * 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
US5508045A (en) * 1992-10-09 1996-04-16 The Regents Of The University Of California Method and agents for control and management of labor during pregnancy
US5344846A (en) * 1992-12-30 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells
US5738096A (en) * 1993-07-20 1998-04-14 Biosense, Inc. Cardiac electromechanics
US5609612A (en) * 1993-10-05 1997-03-11 Sorin Biomedica Cardio S.P.A. Device for determining myocardial function and corresponding procedure and method
US5865738A (en) * 1993-12-10 1999-02-02 Regents Of The University Of California Tissue viability monitor
US5686649A (en) 1994-03-22 1997-11-11 The Rockefeller University Suppression of plant gene expression using processing-defective RNA constructs
US5546949A (en) * 1994-04-26 1996-08-20 Frazin; Leon Method and apparatus of logicalizing and determining orientation of an insertion end of a probe within a biotic structure
US5722419A (en) * 1994-11-30 1998-03-03 Semmlow; John L. System for determining the viability of tissue
US5544656A (en) * 1994-12-02 1996-08-13 The Regents Of The University Of California Method and apparatus for myocardial wall measurement
HUP9801681A3 (en) * 1995-02-13 2000-10-30 Novartis Ag Mutant proteins
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5849587A (en) * 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
US5727552A (en) * 1996-01-11 1998-03-17 Medtronic, Inc. Catheter and electrical lead location system
US5948771A (en) * 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
US6214572B1 (en) * 1996-08-09 2001-04-10 The General Hospital Corporation Programmed cell death and ICH-3
US6024703A (en) * 1997-05-07 2000-02-15 Eclipse Surgical Technologies, Inc. Ultrasound device for axial ranging
US6124091A (en) * 1997-05-30 2000-09-26 Research Corporation Technologies, Inc. Cell growth-controlling oligonucleotides
US5749831A (en) * 1997-06-23 1998-05-12 Baker; Donald A. Fetal cardiac monitoring utilizing umbilical blood flow parameters and heartbeat information
EP1002079A2 (de) 1997-06-30 2000-05-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Zellwachstumshemmer
US5792199A (en) * 1997-07-24 1998-08-11 Pacesetter, Inc. Pacemaker having rate responsive transducer and method for operating same
US6490474B1 (en) * 1997-08-01 2002-12-03 Cardiac Pathways Corporation System and method for electrode localization using ultrasound
SE9702876D0 (sv) * 1997-08-06 1997-08-06 Pacesetter Ab A cardiac monitoring device and rate responsive pacemaker system
US5836985A (en) * 1997-09-18 1998-11-17 The Regents Of The University Of Michigan Method for treating abnormal arial or ventricular activity
US5991660A (en) * 1997-09-18 1999-11-23 The Regents Of The University Of Michigan Cardiac pacing methods
US6277077B1 (en) * 1998-11-16 2001-08-21 Cardiac Pathways Corporation Catheter including ultrasound transducer with emissions attenuation
US6398736B1 (en) * 1999-03-31 2002-06-04 Mayo Foundation For Medical Education And Research Parametric imaging ultrasound catheter
US6298269B1 (en) * 1999-04-19 2001-10-02 Cardiac Pacemakers, Inc. Cardiac rhythm management system with ultrasound for autocapture or other applications
US6538182B1 (en) 1999-07-06 2003-03-25 Senesco, Inc. DNA encoding a plant deoxyhypusine synthase, a plant eukaryotic initiation factor 5A, transgenic plants and a method for controlling senescence programmed and cell death in plants
JP2003510250A (ja) 1999-08-06 2003-03-18 ファルマシア・アンド・アップジョン・カンパニー スタフィロコッカス・アウレウス延長因子ｐの結晶化および構造決定
US6443894B1 (en) * 1999-09-29 2002-09-03 Acuson Corporation Medical diagnostic ultrasound system and method for mapping surface data for three dimensional imaging
US6491639B1 (en) * 1999-11-10 2002-12-10 Pacesetter, Inc. Extravascular hemodynamic sensor
US6450977B1 (en) * 2000-04-10 2002-09-17 Cervilenz Devices and methods for cervix measurement
US7217517B2 (en) * 2001-07-23 2007-05-15 Senesco Technologies, Inc. Nucleic acids, polypeptides, and methods for modulating apoptosis
US7381708B2 (en) * 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
US7968523B2 (en) * 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis

Also Published As

Publication number Publication date
US20070059831A1 (en) 2007-03-15
EP1546375A2 (de) 2005-06-29
US20030064952A1 (en) 2003-04-03
WO2003010286A9 (en) 2003-12-31
US7166467B2 (en) 2007-01-23
EP1546375B1 (de) 2010-11-24
CN1636064A (zh) 2005-07-06
KR100944938B1 (ko) 2010-03-02
JP2011103892A (ja) 2011-06-02
JP2005519583A (ja) 2005-07-07
WO2003010286A3 (en) 2005-05-06
CA2454822A1 (en) 2003-02-06
CA2454822C (en) 2014-09-23
AU2002324519B2 (en) 2008-05-15
KR20040014670A (ko) 2004-02-14
AU2002324519A2 (en) 2003-02-17
CN100352923C (zh) 2007-12-05
EP1546375A4 (de) 2006-11-08
WO2003010286A2 (en) 2003-02-06
ATE489478T1 (de) 2010-12-15
US7872112B2 (en) 2011-01-18
US20120064625A1 (en) 2012-03-15
CA2857312A1 (en) 2003-02-06
DE60238449D1 (de) 2011-01-05
NZ531225A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
EP1546375A4 (de) Nukleinsäuren, polypeptide und verfahren zur apoptosemodulation
EP1509251A4 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis
HUT72189A (en) Rapamycin effector proteins, dna molecules which encode proteins, anti-sense dna molecules which hibridize with dna molecules, processes for isolating rapamycin effector proteins, for identifying immunomodulators, for detecting rapamycin analogs and ...
ATE318905T1 (de) Homologe des tie-rezeptortyrosinekinase liganden
YU84303A (sh) Postupak dobijanja cetp inhibitora
BE2010C021I2 (de)
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression
WO2004007664A3 (en) Nucleic acid vectors
WO2002060917A3 (en) Method to treat hemophilia
ATE171212T1 (de) Corticotropin freisetzende rezeptoren des faktor 2
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
ATE495255T1 (de) Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
AU6724794A (en) GRB3-3 gene, its variants and their uses
WO2003057843A8 (en) Methods and materials for modulating trpc4
ZA97835B (en) Purified sr-p70 protein
AU7216498A (en) Inhibitors of the urokinase receptor
WO2003057847A8 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
WO2006060823A3 (en) Apoptosis-specific eif-5a and polynucleotides encoding same
WO2002070699A3 (en) Cofactors of the estrogen receptor alpha and methods of use
WO2000065055A8 (en) Human transporter proteins
WO2003057898A8 (en) Methods and materials for modulating p2x2
WO2002048353A3 (de) Dna-sequenzen, codierend für ein apoptose-signaltransduktionsprotein
WO2000063352A3 (en) Human homologues of fused gene
AU3539301A (en) Process for the synthesis of vertebrate telomeric dna, products thus obtained and corresponding uses
WO2003057846A3 (en) Methods and materials for modulating task-3